

ABSTRACT OF THE DISCLOSURE

A therapeutic suspension for the treatment of human immunodeficiency virus type I (HIV-1) infection in humans using isolated and purified HIV-1 *nef*-deficient viral particles having a
5 *nef*-deletion between the endonuclease cleavage sites Nco I and Xho I.